Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 223,651,241 papers from all fields of science
Search
Sign In
Create Free Account
AL 6598
Known as:
AL-6598
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Dinoprost
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.
C. Toris
,
G. Zhan
,
M. Feilmeier
,
C. Camras
,
M. Mclaughlin
Journal of Ocular Pharmacology and Therapeutics
2006
Corpus ID: 30692534
This study examines, in 11 cynomolgus monkeys with unilateral laser-induced glaucoma, the ocular hypotensive mechanism of action…
Expand
2005
2005
Ocular hypotensive DP-class prostaglandin receptor affinities determined by quantitative autoradiography on human eye sections.
N. Sharif
,
T. Davis
,
G. Williams
Journal of Ocular Pharmacology and Therapeutics
2005
Corpus ID: 45721582
The aim of this study was to define the localization and pharmacology of DP-prostaglandin receptors in human eye sections using a…
Expand
2004
2004
Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes.
N. Sharif
,
G. Williams
,
J. Crider
,
Shouxi X. Xu
,
T. Davis
Journal of Ocular Pharmacology and Therapeutics
2004
Corpus ID: 45924715
DP-class prostaglandins and prostaglandin analogs (collectively, prostaglandins or PGs) such as PGD2, BW245C, ZK110841, and…
Expand
2002
2002
3-Oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents.
M. Hellberg
,
R. Conrow
,
+13 authors
P. Klimko
Bioorganic & Medicinal Chemistry
2002
Corpus ID: 22384460
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required